An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
Maruthi R. Akella, an aerospace scientist and control systems engineer from the University of Texas…
President Droupadi Murmu distributed the National Sports Awards 2025 on 13th November 2026. A total…
A global Microsoft outage on November 12, 2026 affected a range of services including Outlook,…
Nvidia has appointed Colette Kress as its interim chief executive officer (CEO), following Jensen Huang's…
Prime Minister Narendra Modi will travel to Manila, Philippines on 16 and 17 November 2026…
India is taking steps to boost its domestic space intelligence capabilities with an Artificial Intelligence-based…